Skip to main content
. 2021 May 26;44(12):2845–2847. doi: 10.1007/s40618-021-01563-y

Fig. 1.

Fig. 1

Changes in the prevalence of metabolic syndrome, dyslipidemia, impaired fasting glucose/diabetes mellitus, arterial hypertension and obesity after COVID-19 outbreak. Consequently to the restrictive measures required for COVID-19 pandemics and total lockdown, prevalence of metabolic syndrome, dyslipidemia and obesity significantly increased in the present cohort of hyperprolactinemic or osteoporotic patients without pre-existing metabolic disorders before COVID-19 outbreak